This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group database
Blood Cancer Journal Open Access 05 September 2023
-
Bortezomib-based consolidation or maintenance therapy for multiple myeloma: a meta-analysis
Blood Cancer Journal Open Access 06 March 2020
-
Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later
Drugs in R&D Open Access 16 April 2019
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Ludwig H, Miguel JS, Dimopoulos MA, Palumbo A, Garcia SR, Powles R et al. International Myeloma Working Group recommendations for global myeloma care. Leukemia 2014; 28: 981–992.
Cavo M, Pantani L, Petrucci MT, Patriarca F, Zamagni E, Donnarumma D et al. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood 2012; 120: 9–19.
Leleu X, Fouquet G, Hebraud B, Roussel M, Caillot D, Chretien ML et al. Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma. Leukemia 2013; 27: 2242–2244.
Mellqvist UH, Gimsing P, Hjertner O, Lenhoff S, Laane E, Remes K et al. Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial. Blood 2013; 121: 4647–4654.
Bladé J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102: 1115–1123.
Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467–1473.
Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 2011; 12: 431–440.
Avet-Loiseau H, Soulier J, Fermand JP, Yakoub-Agha I, Attal M, Hulin C et al. Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone. Leukemia 2010; 24: 623–628.
Vincent Rajkumar S . Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management. Am J Hematol 2014; 89: 999–1009.
Neben K, Lokhorst HM, Jauch A, Bertsch U, Hielscher T, van der Holt B et al. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood 2012; 119: 940–948.
Sonneveld P, Schmidt-Wolf IG, van der Holt B, El JL, Bertsch U, Salwender H et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. J Clin Oncol 2012; 30: 2946–2955.
Acknowledgements
We thank the patients who participated in these trials and their families, as well as the investigators and staff at all MMY-3012/3013 clinical sites in Germany, as part of the German Multiple Myeloma Study Group (DSMM). We also like to acknowledge the writing support of Megan Barrett of FireKite, an Ashfield company, part of UDG Healthcare plc, and Mark Richardson, who provided medical writing support on behalf of FireKite, during the development of this manuscript, which was funded by Millennium Pharmaceuticals Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited and Janssen-Cilag GmbH. ClinicalTrials.gov IDs: NCT00416273, NCT00416208. This research was supported by Janssen-Cilag GmbH.
Author contributions
Conception and design: HE, CS, MV. Collection and assembly of the data: All authors. The data analysis and interpretation: HE, CS, MV, JM, PL. Letter writing: All authors. Final approval of the letter: All authors. All authors had full access to the study data and were involved in the decision to submit for publication.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare the following: HE: honoraria (Celgene, Janssen); consulting/advisory role (Celgene, Janssen, Novartis, Amgen); Speakers’ bureau (Celgene, Janssen, Novartis, Amgen); research funding (Celgene, Janssen); travel/accommodation/expenses (Celgene, Janssen, Novartis). MV: employment (Janssen-Cilag GmbH). SK: honoraria (Celgene, Janssen); consulting/advisory role (Celgene, Novartis, Onyx). MK: consulting/advisory role (Celgene, Janssen, Onyx); Speakers’ bureau (Celgene, Janssen, Onyx); travel/accommodation/expenses (Celgene, Janssen). BM: consulting/advisory role (Amgen, Sanofi); travel/accommodation/expenses (Celgene, Takeda). H Sayer: consulting/advisory role (Riemser Pharma). H Salwender: honoraria (Janssen); travel/accommodation/expenses (Janssen). FB: travel/accommodation/expenses (Celgene). MG: research funding (Janssen); travel/accommodation/expenses (Janssen). WR: consulting/advisory role (Janssen); travel/accommodation/expenses (Janssen). ME: honoraria (Celgene, Janssen, MSD); consulting/advisory role (Celgene, Janssen, MSD); research funding (Celgene); travel/accommodation/expenses (Celgene). TF: honoraria (Novartis); consulting/advisory role (Novartis). CS: honoraria (Celgene, Janssen, Onyx); consulting/advisory role (Celgene, Janssen, Onyx); research funding (Celgene, Chugai); expert testimony (Celgene, Onyx); travel/accommodation/expenses (Celgene, Onyx). The remaining authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Leukemia website
Supplementary information
Rights and permissions
About this article
Cite this article
Einsele, H., Knop, S., Vogel, M. et al. Response-adapted consolidation with bortezomib after ASCT improves progression-free survival in newly diagnosed multiple myeloma. Leukemia 31, 1463–1466 (2017). https://doi.org/10.1038/leu.2017.83
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2017.83
This article is cited by
-
Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group database
Blood Cancer Journal (2023)
-
The role of novel agents for consolidation after autologous transplantation in newly diagnosed multiple myeloma: a systematic review
Annals of Hematology (2021)
-
Bortezomib-based consolidation or maintenance therapy for multiple myeloma: a meta-analysis
Blood Cancer Journal (2020)
-
Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later
Drugs in R&D (2019)
-
Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation
Leukemia (2018)